News and Trends 1 Sep 2022 Study of injection to treat schizophrenia to begin after $3M payment received A phase 3 clinical trial for an injection to treat patients with schizophrenia has been initiated after a $3 million payment was received by MedinCell. Teva Pharmaceuticals made the decision to start the trial for mdc-TJK this week (August 29). Schizophrenia is a serious mental disorder in which people interpret reality abnormally. Schizophrenia can produce a […] September 1, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Brainomix awarded tender to deploy AI stroke imaging across whole of Hungary Artificial intelligence (AI) stroke imaging will be deployed across centers in Hungary after Brainomix was awarded a national tender. The company was granted the tender for all stroke centers in the country as part of the National Institute for Health Development initiative to improve stroke care. Following a competitive process, the five-year program that was […] September 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Provention Bio looks to advance diabetes drug through $125M loan U.S. biopharma company Provention Bio, Inc. has secured a term loan facility of up to $125 million with Hercules Capital, Inc. ahead of the company’s potential launch of teplizumab. The BLA for teplizumab, Provention Bio’s lead investigational drug candidate, for the delay of progression to stage 3 clinical type 1 diabetes in at-risk individuals has […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 License agreement signed allowing drug to treat mycosis fungoides to expand in Asia, Australia and the Middle East A license agreement has been signed between Helsinn Group and Juniper Biologics further widening the scope for distribution of T-cell lymphoma treatment, LEGADA. The license signifies a supply agreement to register, distribute, promote, market and sell the drug in Australia, Asia and the Middle East as a topical treatment of the mycosis fungoides-type cutaneous T-cell […] September 1, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Sanofi’s first treatment in the U.S. approved for adults and children with ASMD A rare, inherited disease that affects the body’s ability to metabolize fat, cholesterol and lipids within cells can now be treated by Xenpozyme, a drug approved by the U.S. Food and Drug Administration (FDA). Adults and children with non-central nervous system (non-CNS) manifestations of acid sphingomyelinase deficiency (ASMD) can now take healthcare company Sanofi’s Xenpozyme […] September 1, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Labiotech adds conference and event listings In the past few months, Labiotech.eu has boosted its coverage range to go global, added a podcast, expanded to three weekly newsletters, introduced special monthly newsletters, and now we’ve added another string to our bow – conference and event listings. The page is designed so visitors can easily jump between months and events. Listings have […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
Opinion 1 Sep 2022 The evolution of diabetes management Diabetes management has progressed leaps and bounds in the last 100 years. Francine Kaufman, Chief Medical Officer of Senseonics, outlines how far the field has progressed and what is on the horizon for diabetes patients. This year marks 100 years since insulin was first available to treat diabetes – an incredible milestone. One of the […] September 1, 2022 - 6 minutesmins - By External Contributor Share WhatsApp Twitter Linkedin Email
News and Trends 1 Sep 2022 Ensysce Biosciences and Quotient Sciences to develop opioid to prevent abuse and overdose Ensysce Biosciences, Inc., a clinical-stage biotech company, and Quotient Sciences, a drug development and manufacturing accelerator, are partnering to support the development and clinical testing of PF614-MPAR. PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. Quotient Sciences is currently using […] September 1, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Gel treatment for erectile dysfunction receives positive results from clinical trial Futura Medical has announced positive results from a clinical trial looking into MED3000, a topical gel formulation for the treatment of erectile dysfunction (ED). The results, from the confirmatory phase 3 clinical study, FM71, were announced today (August 31). MED3000 is a breakthrough, fast-acting gel produced by Futura Medical’s transdermal DermaSys drug delivery technology. It […] August 31, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Regulatory approval given to Iceland’s EpiEndo for study of COPD treatment A treatment for chronic respiratory disorders will be the subject of a clinical trial in Iceland after regulatory and ethics approval was granted. EpiEndo Pharmaceuticals will start a clinical trial of its lipopolysaccharide challenge with lead molecule EP395. Available orally, EP395 is an macrolide or Barriolide with reduced antimicrobial activity which aims to address the […] August 31, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Anti-cancer drug created from reprogrammed yeast Engineered yeast cells can synthetically produce the essential cancer medicine vinblastine, an international team of scientists showed in a new study published in Nature. In the summer and fall of 2019, some cancer patients experienced interruptions in their treatment. The reason was a shortage of the drugs vinblastine and vincristine, essential chemotherapeutic medicines for several […] August 31, 2022 - 5 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 31 Aug 2022 Researchers try to bridge gap in link for patients with salmonella infection and clogged arteries Researchers from Taiwan have discovered that patients with non-typhoidal salmonella (NTS) have higher aortic calcification and elevated plasma levels, which are an inflammatory biomarker. They say their findings suggest the need for early diagnosis of the condition in patients with atherosclerosis risk factors. NTS is a foodborne bacterium causing gastrointestinal infections and can cause life-threatening […] August 31, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email